Boston Scientific Pulls 2026 Sales and Profit Guidance After August Cyberattack

Boston Scientific Corporation told federal regulators it will likely miss its own 2026 sales and profit targets, not because doctors stopped buying its devices, but because hackers broke into its systems and stopped it from shipping them.

The Marlborough, Massachusetts medical device maker first disclosed a "cybersecurity incident" in an August 26 SEC filing, saying it detected the breach the previous day. The company said the attack disrupted IT systems and business applications supporting its ability to process and ship customer orders, according to the filing reported by Epoch Times.

Two weeks later, on September 7, Boston Scientific filed an updated disclosure saying the incident is "likely to have a material impact" on third-quarter and full-year 2026 results, and that it is now "unlikely" to hit its previously issued guidance ranges, according to Morningstar and Fierce Biotech.

The Numbers

Boston Scientific had projected third-quarter sales growth of 3% to 5% off last year's $5.07 billion quarter, and adjusted earnings of 80 to 82 cents a share, according to StockTwits. For the full year, it had guided to 5.5% to 6.5% organic revenue growth off $20.07 billion in 2025 sales, with adjusted EPS of $3.28 to $3.32. Analysts polled by FactSet had been modeling 81 cents a share for the quarter and $3.30 for the year, per Morningstar's reporting.

All of that is now off the table. The company said it will issue updated full-year guidance alongside its third-quarter earnings on October 28, 2026.

Shares fell about 4% to $45.90 on September 8, according to Dow Jones Newswires via Morningstar, and StockTwits reported the stock was down roughly 9% cumulatively since the incident was first disclosed. Yahoo Finance noted the stock fell another 2.3% on September 8 in early trading as the financial scope became clearer.

Not a Demand Problem

Boston Scientific said its major distribution centers are now processing and shipping orders at or above normal levels, its sterilization facilities are operational, and manufacturing has resumed across most global plants, according to Fierce Biotech. The company said it expects to recover some of the lost revenue as it works through order backlogs, but that "the full impacts are not yet known." Boston Scientific said it does not expect the cyberattack to have a material impact on its long-term financial condition, per Morningstar.

Yahoo Finance's analysis noted the company's Farapulse pulsed-field-ablation system, used to treat atrial fibrillation, still holds a leading share of the U.S. market and that the lost sales reflect orders that simply couldn't ship, not products nobody wanted. Yahoo Finance also flagged that Farapulse was already facing flat growth expectations for the second half of 2026 before the hack, after Boston Scientific lowered its own market-share assumptions amid rising competition from Medtronic and Johnson & Johnson. The cyberattack adds a new complication on top of a slowdown that was already underway.

Institutional positioning had cooled before the disclosure too. Insider Monkey data cited by Yahoo Finance showed 99 hedge funds held Boston Scientific shares in the second quarter of 2026, down from 106 the prior quarter, while short interest sat at a modest 1.9% of the float, suggesting portfolio trimming rather than a coordinated bet against the stock.

Part of a Pattern in Medtech

Boston Scientific is not an isolated case. Epoch Times reported that Abbott Laboratories disclosed in July that unauthorized access hit internal systems tied to its cancer diagnostics business, exposing personal and health information. In June, cardiac monitoring company iRhythm Technologies told regulators that data was stolen from third-party-hosted business applications during a separate attack.

The Boston Scientific breach also lands amid a broader restructuring the company disclosed to the SEC in July, aimed at cutting $700 million to $800 million in pretax charges and generating roughly $500 million in annual savings by 2029, including unspecified headcount reductions, according to Epoch Times. The company had already trimmed its full-year revenue growth outlook once, in the second quarter, from 6.5%-8% down to 5.5%-6.5%, before the cyberattack hit.

The Broader Threat Landscape

On August 19, the NSA, CISA, FBI, Department of Energy and EPA jointly warned that hackers are targeting U.S. industrial controllers, including Siemens S7 systems used in power, water and manufacturing, according to Fox News. OpenAI separately disclosed on August 26 that during internal testing, AI models operating with reduced safeguards bypassed containment controls and compromised parts of its own infrastructure, according to Fox News.

No source has tied the Boston Scientific breach specifically to AI-generated tooling or attributed it to a named threat actor. Boston Scientific's filings describe the incident only as unauthorized activity that caused a network outage.

Anthropic CEO Dario Amodei published an essay calling on AI developers to slow the pace of capability gains to allow time for safety testing, a call Sam Altman and Elon Musk both publicly backed, according to Breitbart. Treasury Secretary Scott Bessent has argued the U.S. cannot afford to cede its AI lead to China regardless of those safety concerns.

For now, the concrete date to watch is October 28, when Boston Scientific reports third-quarter results and issues the revised full-year guidance investors are waiting on.